A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
LB Pharmaceuticals Inc Common Stock LBRX
Promising (early) broader-coverage candidate · This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression.
On FrontierLab's discovery record since 2026-08-04 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-05), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | 0 |
| Rule of 40 | — |
| Net margin | — |
| Cash runway (months) | 87.1 |
| PEG | — |
| Price / sales | — |
Quality checklist
- ✓ Capital efficiency
- ✗ Share dilution — 11116.4%
Fundamentals — snapshot as of 2026-08-05
| Stage | Early |
|---|---|
| Share issuance (YoY) | 11116.4% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-21.47 |
| Burn multiple | — |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.93 |
| Net debt / EBITDA | — |
| Statements as of | Q1 FY2026 · filed 2026-03-31 |
Momentum context — a snapshot from 2026-08-05, not current
| Price at surface | $45.00 (as of 2026-08-05) |
|---|---|
| 52-week range | $13.36 – $46.005 |
| % off 52-wk high | -2.2% |
| RSI (14) | 80 |
| Relative volume | 1.6× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-05 (end-of-day). How grades are computed →